The Brutalist Report - business
system |
|
- AstraZeneca’s Earnings Beat Shows Momentum, But Can its Pipeline Deliver $80 Billion in Revenue? [1d]
- Novo Nordisk Expands Its AI Push With AWS, But Can It Accelerate Drug Discovery? [1d]
- Nissan scrapped a bank it couldn't afford to build [1d]
- Micron, Sandisk, and SK Hynix: History Says This About the Memory Trio's Rally [1d]
- Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside? [1d]
- Fabrinet Just Lost Billions in Market Value Due to Nvidia. Here’s Why the Reaction Is Overdone. [1d]
- You Can Now Deduct Car Loan Interest but Only if the Final Assembly Happened in America. Here’s How to Check If a Car Qualifies [1d]
- Alkane Resources uncovers new high-grade gold-antimony domain at Costerfield [1d]
- The AI Debt Boom Is Helping Push Everyone’s Cost of Capital Higher [1d]
- Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise? [1d]
- Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff? [1d]
- Retirees can supplement their Social Security with two top dividend stocks [1d]
- Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over? [1d]
- Diesel Crisis Threatens to Outlast the Middle East War [1d]
- Bitwise Just Took $1.8 Billion in a Bear Market, Tom Lee Noticed [1d]
- A Tax Strategy So Aggressive It Built the World’s Largest Hedge Fund and Made Losing Money the Hottest Product on Wall Street [1d]
- Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside? [1d]
- The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up. [1d]
- Prediction: Oklo Won't Book Its First Commercial Power Revenue Before 2028 [1d]
- Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery? [1d]
- The next big oil trade may have nothing to do with oil stocks [1d]
- Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable? [1d]
- The $70M business behind Ballerina Farm [1d]
- Mark Walter Lieutenant Was Key to Dodgers Owner’s Complex Lending Machine [1d]
- Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet? [1d]
- Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can [1d]
- The “Crummey Letter”: The One-Page Note Families Mail Every December to Keep a Million-Dollar Trust Tax-Free. [1d]
- Goldman Sachs spots huge twist ahead of Nvidia’s earnings [1d]
- Thermo Fisher vs. Intuitive Surgical: Which Premium Healthcare Stock Deserves its Valuation? [1d]
- Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside? [1d]
- Micron CEO is doubling down on a cycle-free future [1d]
- Tesla Maintained Its Majority of the U.S. EV Market in Q2, but That's Not All You Need to Know [1d]
- Does Billionaire Bill Ackman Know Something Wall Street Doesn’t? He Invested in These 2 Stocks That Have Dropped 33% and 18% Over the Past Year [1d]
- Liquor industry struggles grow with another Chapter 7 filing [1d]
- How To Earn $500 A Month From Intuit Stock Ahead Of Q4 Earnings [1d]
- Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run [1d]
- The Metals Company Is Riding the Critical Metals Boom. Here's Why I Still Wouldn't Touch It. [1d]
- One Social Security Move Boomers Used to Boost Their Checks Is Now Off-Limits to Almost Everyone Else. [1d]
- Pemex and Petrobras Bet Big on High-Risk High-Reward Drilling Off Mexico [1d]
- No new articles in the Past 3 Hours.
Previous Day